TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07861100: Zenagamtide Use for the Reduction of Risk of Major Adverse Cardiovascular Events in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

Sponsor: Novo Nordisk A/S · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 8500 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$11,125,984

Rescue Site Savings

+$7,354,464

Unlock Full NCT07861100 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07861100 Rescue Dossier →